ADC Therapeutics' Study Abstracts Accepted for Presentation at 66th ASH Annual Meeting

ADC Therapeutics SA, a leader in antibody drug conjugates (ADCs), announced that abstracts from investigator-initiated studies on their drug ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California, from December 7-10, 2024. The abstracts focus on the efficacy of ZYNLONTA in combination with rituximab for treating relapsed or refractory follicular lymphoma, and as a single-agent treatment for marginal zone lymphoma.

Data from a Phase 2 study of ZYNLONTA combined with rituximab in patients with high-risk relapsed or refractory follicular lymphoma showed a promising overall response rate of 97.1% at 12 weeks. Among the 35 evaluable patients, all complete metabolic responses were sustained, and 4 out of 10 partial metabolic responses improved by week 21, reaching a best complete metabolic response rate of 80%. Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics, highlighted these robust results and noted that the data support the potential of ZYNLONTA in this combination therapy.

For relapsed or refractory marginal zone lymphoma, ZYNLONTA as a single agent demonstrated an overall response rate of 85% and a complete response rate of 75% among 20 evaluable patients. Dr. Zaki expressed optimism about these findings and emphasized that the safety profile of ZYNLONTA remained consistent with previous data. Further updates on these studies are anticipated at the ASH meeting.

The oral presentation for the investigator-initiated study titled "Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma" will be presented by Dr. Juan Pablo Alderuccio. This session will take place on Saturday, December 7, 2024, from 4:00-5:30 p.m. PT, at the Marriott Marquis San Diego Marina.

Additionally, a poster presentation on the first interim futility analysis of a Phase 2 clinical trial titled "Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma" will be held on Sunday, December 8, 2024. This session will be part of the ASH annual meeting's poster presentations from 6:00-8:00 p.m. PT at the San Diego Convention Center.

ADC Therapeutics, based in Lausanne, Switzerland, and with operations in London and New Jersey, continues to advance its ADC technology to revolutionize treatments for hematologic malignancies and solid tumors. The company's CD19-directed ADC, ZYNLONTA, has received accelerated approval by the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. Ongoing development efforts focus on combining ZYNLONTA with other agents and exploring its use in earlier lines of therapy.

In addition to ZYNLONTA, ADC Therapeutics is developing multiple other ADCs across clinical and preclinical stages. The company's mission is to provide innovative therapies to improve patient outcomes in cancer treatment.

These recent studies underscore the potential of ZYNLONTA in treating challenging lymphoma cases and reflect ADC Therapeutics' commitment to advancing cancer treatment through cutting-edge ADC technology. Further details and updates from the ASH meeting will provide more insights into the efficacy and safety of these promising therapeutic combinations.